Derek W. Bartlett, Ph.D.
Affiliations: | 2007 | Chemical Engineering | California Institute of Technology, Pasadena, CA |
Area:
Catalysis, Molecular TherapyGoogle:
"Derek Bartlett"Mean distance: 10.6
Parents
Sign in to add mentor| Mark E. Davis | grad student | 2007 | Caltech | |
| (An Engineering Approach to Cancer Therapy Using Systemically Delivered siRNA.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Viola-Villegas NT, Sevak KK, Carlin SD, et al. (2014) Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives. Molecular Pharmaceutics. 11: 3965-73 |
| Olafsen T, Bartlett D, Ho D, et al. (2014) Minibody imaging of prostate-specific membrane antigen (PSMA): From concept to clinic. Journal of Clinical Oncology. 32: e16057-e16057 |
| Gudas J, Olafsen T, Ho D, et al. (2013) Abstract LB-351: Evaluation of two engineered antibody fragments derived from a human CD20 antibody as tracers for immunoPET . Cancer Research. 73 |
| Bartlett DW, Davis ME. (2008) Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnology and Bioengineering. 99: 975-85 |
| Bartlett DW, Su H, Hildebrandt IJ, et al. (2007) Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proceedings of the National Academy of Sciences of the United States of America. 104: 15549-54 |
| Heidel JD, Liu JY, Yen Y, et al. (2007) Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2207-15 |
| Bartlett DW, Davis ME. (2007) Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjugate Chemistry. 18: 456-68 |
| Bartlett DW, Davis ME. (2007) Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnology and Bioengineering. 97: 909-21 |
| Bartlett DW, Davis ME. (2007) Characterization and in vivo efficacy of targeted nanoparticles for systemic siRNA delivery to tumors 2007 Nsti Nanotechnology Conference and Trade Show - Nsti Nanotech 2007, Technical Proceedings. 2: 763-766 |
| Schluep T, Hwang J, Cheng J, et al. (2006) Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1606-14 |